These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 21463285)

  • 21. Stiripentol for the treatment of seizures in Dravet syndrome.
    Eschbach K; Knupp KG
    Expert Rev Clin Pharmacol; 2019 May; 12(5):379-388. PubMed ID: 31017478
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stiripentol for the treatment of seizures associated with Dravet syndrome in patients 6 months and older and taking clobazam.
    Vasquez A; Wirrell EC; Youssef PE
    Expert Rev Neurother; 2023 Apr; 23(4):297-309. PubMed ID: 36975187
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ketogenic diet in patients with Dravet syndrome.
    Caraballo RH; Cersósimo RO; Sakr D; Cresta A; Escobal N; Fejerman N
    Epilepsia; 2005 Sep; 46(9):1539-44. PubMed ID: 16146451
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Severe myoclonic epilepsy in infancy (Dravet's syndrome). Its nosological characteristics and therapeutic aspects].
    Nieto Barrera M; Candau Fernandez Mensaque R; Nieto Jiménez M
    Rev Neurol; 2003 Jul 1-15; 37(1):64-8. PubMed ID: 12861512
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changing Landscape of Dravet Syndrome Management: An Overview.
    Samanta D
    Neuropediatrics; 2020 Apr; 51(2):135-145. PubMed ID: 32079034
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group.
    Chiron C; Marchand MC; Tran A; Rey E; d'Athis P; Vincent J; Dulac O; Pons G
    Lancet; 2000 Nov; 356(9242):1638-42. PubMed ID: 11089822
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effects of stiripentol on GABA(A) receptors.
    Fisher JL
    Epilepsia; 2011 Apr; 52 Suppl 2(0 2):76-8. PubMed ID: 21463286
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stiripentol: an example of antiepileptic drug development in childhood epilepsies.
    Nabbout R; Chiron C
    Eur J Paediatr Neurol; 2012 Sep; 16 Suppl 1():S13-7. PubMed ID: 22695038
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stiripentol efficacy and safety in Dravet syndrome: a 12-year observational study.
    Myers KA; Lightfoot P; Patil SG; Cross JH; Scheffer IE
    Dev Med Child Neurol; 2018 Jun; 60(6):574-578. PubMed ID: 29473155
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of add-on stiripentol to clobazam and valproate in Japanese patients with Dravet syndrome: additional supportive evidence.
    Inoue Y; Ohtsuka Y;
    Epilepsy Res; 2014 May; 108(4):725-31. PubMed ID: 24630050
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The European patient with Dravet syndrome: results from a parent-reported survey on antiepileptic drug use in the European population with Dravet syndrome.
    Aras LM; Isla J; Mingorance-Le Meur A
    Epilepsy Behav; 2015 Mar; 44():104-9. PubMed ID: 25666511
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of pediatric epilepsy: European expert opinion, 2007.
    Wheless JW; Clarke DF; Arzimanoglou A; Carpenter D
    Epileptic Disord; 2007 Dec; 9(4):353-412. PubMed ID: 18077226
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Dravet syndrome as a cause of epilepsy and learning disability].
    Lund C; Bremer A; Lossius MI; Selmer KK; Brodtkorb E; Nakken KO
    Tidsskr Nor Laegeforen; 2012 Jan; 132(1):44-7. PubMed ID: 22240828
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Economic Evaluation of Stiripentol for Dravet Syndrome: A Cost-Utility Analysis.
    Elliott J; McCoy B; Clifford T; Wells GA; Coyle D
    Pharmacoeconomics; 2018 Oct; 36(10):1253-1261. PubMed ID: 29761351
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Extending the use of stiripentol to other epileptic syndromes: a case of PCDH19-related epilepsy.
    Trivisano M; Specchio N; Vigevano F
    Eur J Paediatr Neurol; 2015 Mar; 19(2):248-50. PubMed ID: 25510386
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Add-on stiripentol elevates serum valproate levels in patients with or without concomitant topiramate therapy.
    Jogamoto T; Yamamoto Y; Fukuda M; Suzuki Y; Imai K; Takahashi Y; Inoue Y; Ohtsuka Y
    Epilepsy Res; 2017 Feb; 130():7-12. PubMed ID: 28081475
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment-Refractory Dravet Syndrome: Considerations for Novel Medications.
    Lopez JC; Pare JR; Blackmer AB; Orth LE
    J Pediatr Health Care; 2022; 36(5):479-488. PubMed ID: 35987555
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacologic treatment of the catastrophic epilepsies.
    Conry JA
    Epilepsia; 2004; 45 Suppl 5():12-6. PubMed ID: 15283706
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nonpharmacologic treatments of Dravet syndrome: focus on the ketogenic diet.
    Caraballo RH
    Epilepsia; 2011 Apr; 52 Suppl 2():79-82. PubMed ID: 21463287
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An Update on Stiripentol Mechanisms of Action: A Narrative Review.
    Bacq A; Depaulis A; Castagné V; Le Guern ME; Wirrell EC; Verleye M
    Adv Ther; 2024 Apr; 41(4):1351-1371. PubMed ID: 38443647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.